ABT-773: pharmacokinetics and interactions with ranitidine and sucralfate.
Article Details
- CitationCopy to clipboard
Pletz MW, Preechachatchaval V, Bulitta J, Allewelt M, Burkhardt O, Lode H
ABT-773: pharmacokinetics and interactions with ranitidine and sucralfate.
Antimicrob Agents Chemother. 2003 Mar;47(3):1129-31. doi: 10.1128/aac.47.3.1129-1131.2003.
- PubMed ID
- 12604553 [ View in PubMed]
- Abstract
We assessed the pharmacokinetics and interaction of ABT-773 in 12 volunteers receiving ABT-773 alone or concomitantly with ranitidine or sucralfate. Data for 150 mg of ABT-773 were as follows: the maximum concentration of the drug in plasma (C(max)) was 318 ng/ml, its half-life was 5.66 h, and its area under the plasma concentration-time curve from 0 h to infinity (AUC(0- infinity )) was 1,662 ng. h/ml. Coadministration of ranitidine, reduced the C(max) (-25.7%) and AUC(0- infinity ) (-15.8%) significantly. Sucralfate had no impact on the bioavailability of ABT-773.